Genetic Testing Helps Identify People who are at High Risk for AMD

People of all ages — particularly those age 60 and older — should have an annual eye exam that includes dilation of pupils to detect for signs of age-related macular degeneration (AMD). Although it’s considered an incurable eye disease, certain treatments for AMD may delay its progression and help prevent severe vision loss.

At the office of Retina Group of Washington – Virginia – Sterling our team of skilled professionals is trained in the diagnosis and treatment of macular degeneration — a condition seen most frequently in older adults, where damage occurs to the light sensing cells of the macula, the small area at the center of the eye’s retina responsible for most of our central vision.

Personalized medicine has become a trend in many facets of health care, from oncology to cardiology, and genetic testing for AMD signals its foray into eye care. Personalized medicine is the tailoring of medical treatment to the individual characteristics.

One of the most effective diagnostic tools we offer is Macula Risk® PGx, a simple DNA test performed by rubbing a cotton swab on the inside of the patient’s cheek to help identify people who are at high risk for AMD progression. These high risk patients are then monitored regularly and given the appropriate eye therapy for maximum vision preservation based on the their specific genetic profile. Macula Risk® PGx offers the benefits of earlier detection, earlier treatment and better visual outcomes.

Our commitment to your vision

If you are experiencing symptoms of AMD, contact us immediately. At the office of Retina Group of Washington – Virginia – Sterling, we’re dedicated to providing the highest quality of skilled and compassionate eye care. For more information on Macula Risk® PGx and the many services that we provide, give us a call today.